The MOS STIC, a Bnon-inferiority^trial has the following hypothesis: Bthe Fenix® magnetic anal reinforcement device is clinically as effective as SNS, but more cost-effective in managing severe FI^. Although of a very similar design as compared to SaFaRI, MOS STIC has some perceptible differences such as less investigating centres (n 10) as such a trial involves only highly specialised units, a lower number of patients (n 156) for a shorter study duration (2 years).
In line with the trial hypothesis, to demonstrate efficiency, the selected primary study endpoint is a ≥ 50 % reduction in the average number of incontinence episodes per week as recorded in a 3-week bowel diary. This endpoint is measured at 6 months, a delay long enough to appreciate the treatment effect and not at 18 months as for SaFaRI. As well to determine the cost-effectiveness of Fenix® in comparison with that of SNS, secondary trial objectives include a detailed medico-economic study to record individual medical benefit, the benefits to the community, and the costs associated with the use of two treatment modalities.
Recruitment of patients into MOS STIC trial will end in May 2016 as a request from the sponsor and results will be disclosed soon after.
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